News articles about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DBV Technologies earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.5201962793913 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of brokerages have weighed in on DBVT. Jefferies Group LLC reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a report on Tuesday, September 12th. BidaskClub downgraded shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a report on Tuesday, September 12th. Finally, ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $50.50.

DBV Technologies (NASDAQ DBVT) traded down 1.30% during mid-day trading on Friday, reaching $43.26. The company’s stock had a trading volume of 161,545 shares. The company’s market cap is $1.99 billion. The stock’s 50 day moving average is $44.12 and its 200 day moving average is $37.74. DBV Technologies has a 12 month low of $31.87 and a 12 month high of $46.33.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Insider Buying and Selling by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with's FREE daily email newsletter.